3 Things to Know About Moderna’s mRNA Flu Vaccine and Its FDA Application
•February 26, 2026
0
Why It Matters
Regulatory flip‑flops risk stalling mRNA flu vaccine rollout and undermine confidence in novel vaccine platforms, affecting both public health outcomes and biotech investment.
Key Takeaways
- •FDA reversed its decision, will review Moderna’s mRNA flu vaccine
- •Approval hinges on fast‑track pathway for adults 65+
- •Industry investment wanes as regulatory expectations constantly shift
- •Federal funding cuts threaten broader mRNA vaccine development efforts
- •Policy flip‑flops fuel public mistrust and misinformation about vaccines
Summary
The video examines the FDA’s sudden reversal on Moderna’s mRNA influenza vaccine, shifting from an initial refusal to a green light for a fast‑track review aimed at adults aged 65 and older. The agency had already examined the application, but public backlash prompted a rapid policy change, positioning the vaccine for potential rollout by the next flu season.
Key points include the volatile regulatory environment that discourages biotech firms from investing in mRNA flu research, as shifting rules increase risk. Additionally, the federal government has slashed hundreds of millions in mRNA vaccine funding, further constraining development pipelines. The fast‑track designation specifically targets seniors, reflecting a strategic focus on high‑risk populations.
The presenter notes that the FDA’s initial refusal was met with intense criticism, leading to a swift reversal despite the agency having previously cleared the submission. The ultimate goal is to have an mRNA flu shot available for older adults by the upcoming flu season, but the back‑and‑forth decision underscores systemic uncertainty.
These dynamics could delay market entry, erode investor confidence, and amplify public skepticism toward mRNA technologies, potentially hindering broader adoption of next‑generation vaccines.
Original Description
Reversing course on its surprise refusal to review Moderna’s mRNA flu vaccine, the FDA has now agreed to consider the company’s application.
Jessica Malaty Rivera breaks down what the news means and outlines concerns from the flip-flop decision.
For more information about mRNA vaccines: https://publichealth.jhu.edu/2025/risks-of-cuts-to-mrna-vaccine-development
0
Comments
Want to join the conversation?
Loading comments...